Improve Quality Or You Are Out, Says China FDA Commissioner
This article was originally published in PharmAsia News
Executive Summary
In a rare public speech, China FDA commissioner Bi Jingquan has called for improved drug quality and an ecosystem to reward high quality medicines, highlighting the agency’s drive to step up enforcement amid another recent scandal that has revealed broad quality problems.
You may also be interested in...
FDA Warning Letter Could Impact Zhejiang Medicine’s US Foray
Zhejiang Medicine has become the latest major Chinese API firm to be hit with a US FDA warning letter amid stepped up oversight of production facilities in China by the US regulator, which has led to a string of similar actions this year alone. But efforts are now being made both by Chinese manufacturers and by authorities in the two countries to ensure adherence to international standards.
FDA Warning Letter Could Hamper Zhejiang Medicine’s US Foray
A recent US FDA warning letter could affect efforts by major Chinese API firm Zhejiang Medicine to build its US business, amid falling North American exports from China and a string of similar warnings over the past few years. But efforts are being made both by Chinese manufacturers and by US and Chinese regulators to ensure adherence to international standards.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.